Tech Support


This line is for technical support.
For General Enquiries please click General Contact


Empower Your Model Selection Strategy to Enhance Preclinical Candidate Success

December 4 - 6, 2019


Patient-Derived Experimental Models for Translational Cancer Research

Thursday 5th December, 9:00am
Dr Ludovic Bourré, Senior Director, Scientific Engagement

Learn how to advance oncology drug development through using clinically-relevant patient-derived models, including in vivo PDX, and in vitro patient-derived organoids (PDO) and PDX-derived organoids (PDXO). Find out how to adopt the right model for the right study across oncology therapeutics, and how paired models provide a pioneering platform for translational cancer research.

Poster Presentations

Establishing a Large Tumour Organoid Biobank using a Well-Characterised/Annotated Patient-Derived Xenograft (PDX) Library to Enable Drug Discovery and Translational Research

During evening reception, Thursday 5th December

Explore the generation of over 100 PDX-derived organoids (PDXO) across a range of cancer types using IP-protected Hubrecht Organoid Technology (HUB) protocols. Learn how standard of care PDXO in vitro sensitivity data largely correlate to in vivo PDX treatment response, and why matched in vitro PDXO/in vivo PDX models are an important tool for future oncology drug discovery and development.


Establishment of Orthotopic Syngeneic Models using Bioluminescent Imaging to Recapitulate the Tumour Microenvironment and Evaluate Immunotherapies

During evening reception, Thursday 5th December

Review the development of bioluminescent, orthotopic syngeneic models , for real-time monitoring of tumour development, progression, and treatment response with a more clinically-relevant tumour microenvironment. Compare therapeutic response and treatment data for models versus subcutaneous implantation.


Arrange a Meeting Tumour Models London

Your privacy is important to us.
We'll never share your information.